New Data for Bioerodible DURAVYU in Wet AMD

Tarek S. Hassan provides perspective on the Phase 3 LUGANO topline results and the path forward for DURAVYU in wet age-related macular degeneration (AMD)

September 17, 2026
5 min

The Ophthalmologist

Objective:

To evaluate the efficacy and safety of DURAVYU (EYP-1901) in comparison to aflibercept in patients with wet AMD.

Approach:

Trial Design: The LUGANO trial was a randomized, double-masked Phase 3 study comparing DURAVYU 2.7 mg to aflibercept 2 mg every 8 weeks.
Primary Endpoint: The primary endpoint was the mean change in best-corrected visual acuity (BCVA), which was not met in the full dataset.
Secondary Endpoints: Key secondary endpoints showed strong anatomic control, durability, and reduced treatment burden.

Key Findings:

Mean vision improved in the full DURAVYU cohort despite not meeting the primary endpoint.
Nine patients in the DURAVYU group experienced ≥15-letter vision loss from causes not related to neovascular AMD.
DURAVYU demonstrated a 42% reduction in treatment burden compared to aflibercept.
76% of DURAVYU-treated patients remained supplement-free at Week 32.